Press Release

Advanced Features of Remote Controller Specifically Developed to Deliver an Enhanced User Experience During Endovascular Procedures HINGHAM, Mass. , Nov. 18, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), in a continuation of its efforts to create barriers and expand its global

Th e “ Access-Ability Live” by MBOT will build an online community of healthcare industry leaders who are interested in robotics to come together and share their opinion and experience F irst Webinar on November 16 th at 1:00   pm ET will Focus on the Evolving Endovascular Space   P rocedure s and

Corresponding Application Previously Granted in the U.S. as the Company Continues to Create Global Barriers to Entry for its Novel Technology HINGHAM, Mass. , Nov. 03, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) continues to aggressively protect its global intellectual property

Growing SAB Roster Includes 11   KOLs from Across the U.S. , Europe , and Israel Expansion of KOL Presence and Global Centers of Excellence Continues to Accelerate the Progression of the LIBERTY ® Robotic System to Meet Future Regulatory and Commercialization Milestones HINGHAM, Mass. , Oct.

HINGHAM, Mass. , Oct. 25, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has closed its previously announced registered direct offering with a single institutional investor for the purchase and sale of 1,022,495 shares of the Company’s common stock (which

HINGHAM, Mass. , Oct. 21, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale of 1,022,495 shares of the Company’s common stock (which includes pre-funded

HINGHAM, Mass. , Oct. 18, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), announced that it has submitted the anticipated follow-up pre-submission package for the LIBERTY ® Robotic System to ensure the Company remains fully aligned with the U.S.

HINGHAM, Mass. , Oct. 13, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announced a significant development milestone as it completed the GLP animal study for the LIBERTY® Robotic System, the first disposable robotic system being developed for endovascular procedures.

Suspending Development of SCS and Evaluating Alternatives for SCS Assets HINGHAM, Mass. , Oct. 11, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) has announced that, following the recent acquisition of the endovascular assets of Nitiloop Ltd.